2025-08-28 LabMCoP Meeting Notes

2025-08-28 LabMCoP Meeting Notes

Date

Aug 28, 2025

Attendees

Present

Name

Organization

Present

Name

Organization

X

Nancy Cornish

CDC

X

Manjula Dharmawardhana

CDC

X

Riki Merrick

APHL

X

Christina Gallegos

APHL

X

Amy Liu

Inductive Health / APHL

 

Raj Dash

Duke / CAP

 

John Snyder

 

X

Andrea Pitkus

UW

X

Kathy Walsh

Labcorp

 

Rob Hausam

Hausam Consulting

 

Pam Banning

 3M

Discussion topics

Upcoming OOO

 

 

Lab tests as procedures or orderables

not discussed

Definition from SNOMED for these hierarchies:

  • Observable entity: Information about a quality/property to be observed and how it will be observed

  • Evaluation procedure: No definition, other than it uses attributes that are similar to those used in the Observable entity hierarchy.  Our policy is to not add any new evaluation procedures that would logically be in the Observable entity hierarchy.

  • Technique is a separate hierarchy used to model observable entities: A technique (also called method) is a particular way of performing an activity or task.

Colonoscopy example:

Reference links:

clinical guidelines: Official journal of the American College of Gastroenterology | ACG

Quality Indicators: Official journal of the American College of Gastroenterology | ACG

Discussion:

 

Specimen CMT terms review

Christina

  • Stool_formalin10Isotone

    • rename to what we have in SPM-6: = MPV_CuSO4Formalin10

    • micro domain? yes is for Ova and Parasites (micro review) 0 see

  • SerumThrombinGel

    • gel depends on vendors (not sharing exact ingerdients) - there is no SCT code for the gel (generic, not sure we can get one- Riki to reach out to Raja to find out if we have new SNOMED author for US center)

    • or switch all blood and stool terms to NOT use the SPM-6 and rather use SPM-27 to identify the container types (not well supported) - put on hold

  • Endometrial currettings

    • Pipel biopsy = tube of tissue, while curretage is scraping of the endometrium - we might not have that one yet - needed for AP, which we have

    • For the CMT we will model using curretage procedure

      • for the long term we should work with SNOMED CT to remodel the procedure hierarchy as per this email chain

 

FHIR conceptMap Follow Up

Riki

Specimen CMT draft profile on ConceptMap:

Riki requested agenda time when it works for both of us

 

Call adjourned

 

12:01 PM ET

 

European Semantic work

not discussed

Link to the German FHIR IG around suceptibility testing:

https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsimplifier.net%2Fguide%2Fars-implementation-guide%3Fversion%3Dcurrent&data=05%7C02%7Criki.merrick%40aphl.org%7Ce11e8daf7f2d4827d07808ddcac8861c%7C434e0aedef824568a0493b17adc08ddd%7C1%7C0%7C638889684844672822%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=kZJRoBl2tMQzWQoYVkaRnEUaaBxepA9sAIu1myDQMyo%3D&reserved=0

Semantic Example section: https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsimplifier.net%2Fguide%2FARS-Implementation-Guide%2FHome%2FSemantics%3Fversion%3Dcurrent&data=05%7C02%7Criki.merrick%40aphl.org%7Ce11e8daf7f2d4827d07808ddcac8861c%7C434e0aedef824568a0493b17adc08ddd%7C1%7C0%7C638889684844702198%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qQH%2Ff5xwG0O8DvNE4rbjZineXBhY%2BiOWmN047DRthNQ%3D&reserved=0

 

Creating Value Sets for specimen related attributes

not discussed

  • Specimen reject reason table review - review the “unsatisfactory for evaluation due to …” concepts

 

Previous Action Items

not discussed

 

Specimen CMT - Hosting Options

not discussed

  • How can we publish the content in the dB?

  • SNOMED CT Extension and use of RefSets (start with VSAC value sets as proof of concept and then migrate over) to indicate:

    • preferred specimen types by domain

    • maybe also terms that need additional attributes (by kind of attribute) if we also write an implementation guide for it

  • How do we decide what format to share this in - get input from EHR-s and LIS vendors:

    • Write letter of mulitple stakeholders to request EHR-s and LIS vendors to implement

      • indicating that this is a patient safety issue, as incorrect Abx treatment will contribute to multi-drug resistance (use CTSI findings to provide background)

      • focus on blood, urine, wound cultures (get data from NHSN, too)

    • Nancy is talking to DHQP about the linkage with specimen collection

    • While we have HIT certification that is for the EHR-s there is currently no enforcement for implementation at the organizations

    • need C-suite buy-in

    • Professional organizations - like CAP and ACOS and AJCC get them to write the synoptic reports (better structuring of data) - for surgical aspects - similar to what CAP has done for Cancer (though they do not have the SCT codes included in the past - may be including SNOMED CT starting in 2025, but they are also using the SCT codes for observables) https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/bulletin/2021/12/synoptic-reporting-for-cancer-surgery-current-requirements-and-future-state/: The four CoC accreditation standards that include synoptic operative reporting requirements apply to sentinel lymph node biopsy for breast cancer (Standard 5.3), axillary lymph node dissection for breast cancer (Standard 5.4), wide local excision for primary cutaneous melanoma (Standard 5.5), and colonic resection for colon cancer (Standard 5.6). These accreditation standards were developed from the evidence-based recommendations for cancer surgery detailed in the Operative Standards for Cancer Surgery manuals.7,8

    • try to get AMA support to get providers to adopt this

    • Reach out to IDSA, too

 

Specimen CMT pilot implementers

not discussed

 

Specimen CMT - education

not discussed

  • Need education for providers and IT folks that helps with set up of the EHR-S / LIS configuration -this can be supported / accomplished? with the Implementaiton Guide we could write

  • if we have a use case of how a patient is impacted on their journey through the healthcare system - CAP created a nice video that showed how patient care was affected by incorrect data https://infobeta.cap.org/shield/

 

Specimen CMT - tracking implementation impact

  • Setting baseline

  • Define metrics

not discussed

 

 

Specimen CMT - Compare to NHS Medical Terminology testing

not discussed

 Will get updated vocab at a later date

 

Future projects for this call after CMT

not discussed

  • In general the call is intended as a forum for ANY messaging related issues to work out.

  • In the past we have

    • reviewed containers re-vive that - and how does that interact with devices (UDI identification?)

    • review code systems around additives (HL70371 and SCT substance and product hierarchies)

    • started work on cross-mapping between HL7 method codes and SNOMED CT procedure / technique concepts

      • American College of Surgeons is working on procedure protocol and synoptic data elements / surgical synoptic reports - we could work with them together on that

    • Look at other HL7 tables that we would want to migrate SCT (i.e., Specimen Condition table, etc.)

 

Recording:

did not record

Chat:

Screenshot 2025-08-28 112954.png
Screenshot 2025-08-28 120157.png

 

 

 

 

 

Action items

Quick decisions not requiring context or tracking

For quick, smaller decisions that do not require extra context or formal tracking, use the “Add a decision…” function here.

Decisions requiring context or tracking

For decisions that require more context (e.g., documentation of discussion, options considered) and/or tracking, use the decision template to capture more information.